Adial Pharmaceuticals expects cash to fund operations into second half of 2025
The Fly

Adial Pharmaceuticals expects cash to fund operations into second half of 2025

Cash and cash equivalents were $5.2 million as of September 30, 2024, compared to $2.8 million as of December 31, 2023. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the second half of 2025 based on currently committed development plans.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App